key: cord-0759180-jl2nb6ab
authors: Ding, Ze-yang; Li, Gan-xun; Chen, Lin; Shu, Chang; Song, Jia; Wang, Wei; Wang, Yu-wei; Chen, Qian; Jin, Guan-nan; Liu, Tong-tong; Liang, Jun-nan; Zhu, Peng; Zhu, Wei; Li, Yong; Zhang, Bin-hao; Feng, Huan; Zhang, Wan-guang; Yin, Zhen-yu; Yu, Wen-kui; Yang, Yang; Zhang, Hua-qiu; Tang, Zhou-ping; Wang, Hui; Hu, Jun-bo; Liu, Ji-hong; Yin, Ping; Chen, Xiao-ping; Zhang, Bixiang
title: Association of liver abnormalities with in-hospital mortality in patients with COVID-19
date: 2020-12-19
journal: J Hepatol
DOI: 10.1016/j.jhep.2020.12.012
sha: f30f7cf18543397436af7cc30d785c92b8a366b6
doc_id: 759180
cord_uid: jl2nb6ab

BACKGROUND AND AIMS: The evolution and clinical significance of abnormal liver chemistries and the impact of hepatitis B infection on outcome in patients with COVID-19 is not well characterized. This study aimed to explore these issues. METHODS: This large retrospective cohort study included 2073 patients with COVID-19 having definite outcomes in Wuhan, China. Longitudinal liver function tests were conducted and determined their associated factors and death risk by multivariate regression analyses. A prognostic nomogram was formulated to predict the survival of patients with COVID-19. The characteristics of liver abnormalities and outcomes of patients with COVID-19 with and without hepatitis B were compared after 1:3 propensity score matching. RESULTS: Of the 2073 patients, 1282 (61.8%) had abnormal liver chemistries during hospitalization, and 297 (14.3%) had a liver injury. The mean levels of AST and D-Bil increased early after symptom onset in deceased patients and showed disparity compared with that in discharged patients throughout the clinical course of the disease. Abnormal admission AST (adjusted hazard ratio [HR]: 1.39, 95%CI: 1.04-1.86, P=0.027) and D-Bil (adjusted HR: 1.66, 95%CI: 1.22-2.26, P=0.001) levels were independent risk factors for mortality due to COVID-19. A nomogram was established based on the results of multivariate analysis and showed sufficient discriminatory power and good consistency between the prediction and the observation. HBV infection in patients did not increase the risk of COVID-19-associated poor outcomes. CONCLUSIONS: Abnormal AST and D-Bil levels at admission were independent predictors of COVID-19 mortality. Therefore, monitoring liver chemistries, especially AST and D-Bil levels, in hospitalized patients with COVID-19, is necessary.

syndrome coronavirus 2 (SARS-CoV-2) infections has spread rapidly worldwide [1] .

As a new, highly contagious disease, COVID-19 was first reported with characteristics of viral pneumonia, such as fever, dry cough, and lymphopenia, with ground-glass opacities on chest computed tomography (CT) imaging. In addition, alterations in liver chemistries were found in patients with COVID-19 [2] . A previous study revealed that liver abnormalities occurred more frequently in severe or critically ill patients with COVID-19 [3] . Pathological examination of liver tissues from deceased patients with COVID-19 confirmed that liver involvement of COVID-19 was characterized by microvesicular steatosis, focal necrosis with infiltration of lymphocytes, and microthrombosis in the portal area [4] . Given the alterations in liver function tests and liver impairment in pathological findings in patients with COVID-19, the clinical course and outcome of patients with COVID-19 having liver abnormalities needed to be explored. In addition, the relationship between liver chemistries and in-hospital deaths due to COVID-19 remains controversial. This large, retrospective cohort study conducted at three centers of a designated hospital for treating COVID-19 in Wuhan, China, reported the dynamic characteristics of alteration in liver chemistries in patients with COVID-19. In addition, the association between liver abnormalities and in-hospital outcomes of patients with COVID-19 was investigated. The present study established a predictive model based on the baseline characteristics at admission in patients with COVID-19, including liver abnormalities. Moreover, the characteristics and outcomes of patients with COVID-19 and hepatitis B, as well as other liver diseases, were described and investigated.

J o u r n a l P r e -p r o o f 8 Information System were reviewed. The data were collected using a standardized data collection form and analyzed by the authors under the Data Process & Application Platform (DPAP, Yidu Cloud). A de-identified patient identification was assigned to each patient in the DPAP to protect confidentiality. A team of experienced clinicians who had been treating patients with COVID-19 reviewed and cross-checked the data.

The attending clinicians were approached when the core data in the patients' medical records were unavailable or if any clarifications were needed.

The laboratory testing of patients during hospitalization was conducted in the clinical laboratory of Tongji Hospital. The real-time polymerase chain reaction of nasal and pharyngeal swab specimens was carried out for testing SARS-CoV-2 RNA as described previously [6] . The laboratory tests included a complete blood count, coagulation profile, serum biochemical tests [including liver and renal function tests, J o u r n a l P r e -p r o o f 9 cardiac troponin I (cTnI), lactate dehydrogenase (LDH), high-sensitivity C-reactive protein (CRP), procalcitonin, and cytokines], hepatitis B-related antigen or antibodies, and hepatitis C-related antibodies. Chest CT scans of every patient were performed.

The frequency of laboratory tests and examinations was determined by the clinicians treating COVID-19, and serial laboratory data were collected until the discharge or death of every patient.

The upper limit of the normal range of liver chemistries was determined at the clinical laboratory of Tongji Hospital and is listed in Supporting Table 2 . Definitions of liver abnormalities (LA), mild liver abnormalities (mLA), types of liver abnormalities, liver injury (LI), acute liver injury (ALI), acute liver failure (ALF), acute-on-chronic liver failure (ACLF), the severity of the disease (severe pneumonia or not), complications such as acute respiratory distress syndrome (ARDS) and septic shock, excessive alcohol assumption, diagnosis of cirrhosis and decompensated cirrhosis, metabolic associated fatty liver disease (MAFLD), hepatitis B, and hepatitis C viral infection are listed in Table 1 and Supporting Table 3 .

Detailed statistical analyses are described in Supporting Methods. All statistical analyses were performed using R software, version 3.5.1 (R Foundation for Statistical Computing), and statistical significance was determined at P <0.05.

J o u r n a l P r e -p r o o f

A total of 2073 patients with COVID-19 were included in the analysis of liver function test abnormalities (Supporting Fig. 1 (Table 1) , whereas the elevation of T-Bil, D-Bil, and ALP was less common. Only seven patients had an isolated elevation of T-Bil. Consistently, kernel density estimates using Gaussian kernels depicted the baseline distributions (tested at admission) and peak values of ALT, AST, ALP, GGT, T-Bil, and D-Bil in patients.

The widest separation of distribution between baseline and peak values were observed for ALT, AST, and GGT levels (Supporting Fig. 2) .

Notably, 73.0% (146/200) of deceased patients had liver abnormalities at admission, J o u r n a l P r e -p r o o f 11 and this incidence of liver abnormalities was higher than that in discharged patients (73.0% vs. 43.4%, P < 0.001). In addition, during hospitalization, the prevalence of liver abnormalities (92.5% vs. 58.6%, P < 0.001) and LI (31.5% vs. 3.6%, P < 0.001) was also higher in deceased patients. Both baseline and peak values of liver indices were higher in the deceased group, except for the incidence of abnormalities in baseline ALT levels. In addition, abnormal AST and D-Bil levels were most commonly found in liver tests of deceased patients at admission and during hospitalization ( Table 2 ).

In the last liver function tests of 1873 discharged patients during hospitalization, 594 (31.7%) still showed liver abnormalities, and LI was not found. The results of detailed liver chemistries showed that elevated ALT (349 patients, 18.6%) and GGT (323 patients, 17.2%) levels were most commonly seen in patients approaching discharge (Supporting Table 5 ). However, in 200 deceased patients, 85% (170/200) showed liver abnormalities, and 35.5% (77/200) showed LI in their last liver function tests before succumbing. In detail, the elevation of AST (117 patients, 58.5%) and D-Bil (104 patients, 52%) were most commonly seen in deceased patients before succumbing (Supporting Table 5 ).

Generalized additive models illustrated the changes in liver chemistries in deceased and discharged patients ( Fig. 1 ). In detail, the mean AST and D-Bil levels in the deceased group increased early after symptom onset and were higher than those in the discharged group throughout the clinical course of COVID-19. Also, the mean levels of ALP, T-Bil, and GGT in the deceased group were comparable with those in the discharged group at the symptom onset of the disease and then elevated and peaked in the late stage of the disease. In addition, the changes in mean ALT levels fluctuated, and the values were close in the deceased and discharged groups. Collectively, the trajectory of liver chemistries was consistent with the prevalence of abnormal liver chemistries from admission to moribund or discharge in deceased and discharged patients.

Acute liver injury (ALI) was found in 10 (0.5%) of 1869 patients without chronic liver diseases during their hospitalization (Supporting Table 4 ), and ultimately, all of J o u r n a l P r e -p r o o f 12 these 10 patients died. ALI occurred on day 18.5 (IQR 16.25-30.75) after symptom onset. The occurrence of hepatic encephalopathy and acute liver failure could not be assessed because 8 of the 10 patients with ALI received invasive mechanical ventilation under sedation. We then noticed that isolated ALI was not found in patients with COVID-19. ARDS, septic shock, acute kidney injury, and cardiac injury were the most common conditions simultaneously occurring with ALI in patients with COVID-19 (Supporting Fig. 3 ).

The association of liver abnormalities with in-hospital death in patients with COVID-19 was explored using Cox proportional hazards model (Supporting Tables 6 and 7). After adjustment for age, gender, high BMI, severe pneumonia at admission, metabolic cardio-cerebrovascular disease, liver disease, chronic pulmonary disease, chronic kidney disease, reduced lymphocyte, and platelet counts and albumin levels, and prolonged PT, elevated IL-6, D-dimer, CRP, LDH, PCT, creatinine, and cTnI levels at admission, liver injury (LI) (HR (95% CI)=4.63 (2.34-9.14), P<0.001) during hospitalization were associated with in-hospital mortality. Among the types of liver abnormalities, patients with cholestatic (HR (95% CI)=3.99(1.43-11.14), P=0.008) and mixed types (HR(95% CI)=4.77(2.41-9.41), P<0.001) of liver abnormalities during hospitalization were independently associated with in-hospital death (Supporting Table 7 ). In addition, adjusted hazard ratios for the associations between specific liver indices and all-cause mortality were also analyzed. Supporting Table 7 shows that patients with abnormal AST, ALP, GGT, T-Bil, or D-Bil levels during hospitalization had a higher mortality risk compared with patients having normal levels of these liver indices. 1.20-2.15, P = 0.001) and 1.57 (95% CI: 1.14-2.16, P = 0.006), respectively. Even among patients without severe pneumonia at admission, those with LI (5.9% vs. 2.0%, P = 0.002) or abnormal AST (9.8% vs. 2.0%, P < 0.001) or D-Bil levels (14.3% vs.

3.0%, P < 0.001) were more likely to have the fatal outcome (Supporting Table 8 ). Next, we visualized the second regression model with a higher C-index using a nomogram. Each prognostic factor was assigned a score based on the top scale of the nomogram. By adding up these scores to the total on the bottom scale, the 14-, 21-, and 28-day overall survival of patients with COVID-19 were predicted (Fig. 3) . The calibration plots on bootstrap resampling validation showed good consistency (Supporting Fig. 4) . In addition, we performed propensity score matching (3:1) for baseline confounders that could possibly interfere with the association of hepatitis B and all-cause mortality. There was no difference in the mortality between patients with HBV and those without liver disease (6.0% vs. 6.2%, P > 0.99). The Kaplan-Meier curves of the matched HBV and normal groups further confirmed that the survival rates and curves of these groups were similar (Fig. 4) . Further, no statistically significant difference in the baseline levels and peak values of liver chemistries were found between the matched HBV and normal groups. The trajectories of liver chemistries in the matched HBV and normal groups were close to each other throughout the clinical course of COVID-19 (Supporting Fig. 6 ).

The characteristics of patients with HCV infection, MAFLD, and cirrhosis in this study are shown in Supporting Table 10 . Three patients with decompensated cirrhosis, who were in the initial cohort of 2601 patients but were excluded from the cohort of 2073 patients, were included for analyzing liver abnormalities in COVID-19 to investigate the impact of COVID-19 on patients with decompensated cirrhosis. The prevalence of liver abnormalities in these patients was higher than that in patients without liver diseases, whereas the prevalence of LI in patients without decompensated liver function was comparable with that in patients without liver diseases. Notably, none of the three patients with COVID-19 and decompensated J o u r n a l P r e -p r o o f 15 cirrhosis was diagnosed as having severe pneumonia at admission, whereas ACLF developed in two (66.7%) patients with a time interval from admission to ACLF of 6 and 7 days. Jaundice and ascites were found in both of these patients, and finally, one patient died on the 14th day after the diagnosis of ACLF (Supporting Fig. 7 ).

This study is one of the largest studies evaluating the prevalence and impact of abnormal liver blood tests in patients with COVID-19. It provides robust evidence about the prevalence, pattern, severity, and dynamic changes in liver abnormalities, as well as associated clinical outcomes, in patients with COVID-19 in Wuhan, China. In addition, the clinical characteristics and outcomes of COVID-19 in patients with preexisting liver diseases, especially in those with hepatitis B, were analyzed.

This study shows that the mild elevation of liver chemistries is most commonly found in patients with COVID-19 and liver abnormalities, whereas LI is relatively rare. However, LI, determined either at admission or during hospitalization, is independently associated with in-hospital death of COVID-19 after adjusting for baseline confounders. The prevalence and prognostic value of abnormal liver chemistries in COVID-19 varies across different studies [7, 8] These characteristics of abnormalities are consistent with those in previous reports from other cities of China [9, 10] , Europe [11, 12] , and the United States [13] . In addition, we first report trajectories of liver chemistries in the clinical course of deceased patients with COVID-19 and found that the mean levels of AST and D-Bil increase early after symptom onset in deceased patients and show disparity compared with that in discharged patients throughout the clinical course of the disease.

Moreover, we observed that abnormal D-Bil is commonly found during the hospital stay of deceased patients with COVID-19, with its prevalence second only to that of abnormal AST level in liver chemistries, despite the fact that abnormal D-Bil levels are not commonly found in patients with COVID-19. Both baseline and peak abnormal AST and D-Bil levels are independently associated with in-hospital death of patients with COVID-19. Future studies should evaluate our observed association between early AST and D-Bil elevation and mortality in patients with COVID-19.

Due to the retrospective design of this study, the causality of liver abnormalities and fatal outcome in COVID-19 cannot be explored. However, this study reports that the liver outcomes, including ALI and ACLF, are rarely found in patients with COVID-19. ALI and ACLF develop in the late stage of the disease and are always accompanied by acute multi-organ injuries, such as ARDS and acute kidney injury.

These results suggest that the liver is unlikely a key organ driving the mortality due to COVID-19, although liver abnormalities are commonly found in COVID-19.

The present study reports the largest cohort of patients with COVID-19 and hepatitis B. The prevalence of hepatitis B in patients with COVID-19 is similar to that in the general Chinese population [14] and is much higher than that in previous reports [15] . This disparity might be because the serological tests of hepatitis B surface antigen were not performed in all enrolled patients in previous studies, and the results of the present study do not support the hypothesis that HBV has an impact on the susceptibility to SARS-CoV-2 infection. In addition, after adjusting baseline characteristics by propensity score matching between groups, the baseline and peak values and trajectory of liver chemistries, the prevalence and patterns of liver abnormalities, and the in-hospital mortality in patients with hepatitis B are comparable with those in patients without liver diseases. These results suggest that HBV infection does not increase the risk of COVID-19-associated poor outcomes. In addition, SARS-CoV-2 infections might not increase the risk of severe liver impairment in patients with hepatitis B and compensated liver function.

In this study, we do not report increased mortality in patients with liver diseases and with compensated liver function. In contrast, a high prevalence of ACLF and in-hospital mortality is reported in three patients with COVID-19 and decompensated cirrhosis. These results are consistent with previous findings that patients with COVID-19 and Child-Turcotte-Pugh (CTP)-B and -C cirrhosis show a significantly higher prevalence of hepatic decompensation events and in-hospital mortality compared with those with CTP-A cirrhosis [13, 16] . Given the high mortality caused by COVID-19 in patients with decompensated cirrhosis, the present study conforms with the suggestion from the EASL-ESCMID position paper that measures should be taken to protect patients with decompensated cirrhosis from SARS-CoV-2 infection [17] .

This study has several limitations. Firstly, selection bias might be inevitable because the study enrolled only inpatients with COVID-19, and 48.9% of patients in the cohort were diagnosed with severe pneumonia at admission, which is not consistent with the real-world situation that most COVID-19 cases are mild or moderate. Secondly, repeated liver function tests were performed by clinicians at different time intervals for each patient. Therefore, patients with severe pneumonia and liver test derangements might undergo a higher number of tests, leading to bias.

Thirdly, liver abnormalities at admission might be influenced by preexisting liver diseases or other basic conditions of patients, but the pre-hospital status of liver function tests of patients could not be retrieved from the present cohort. Finally, this is a retrospective and observational study, and hence a validation cohort could not be set up to assess the accuracy of the predictive model due to the urgent circumstance of the pandemic. However, the bootstrap resampling cohort was used, and the ideal C-index of the model was presented. Moreover, the calibration curves for survival probability also showed good consistency between the prediction and the observation. Liver injury (LI) liver injury was defined according to clinical guidelines of ACG and BSG in evaluation of abnormal liver blood tests [1, 2] and the definition used in previous studies in COVID-19 patients [3] . In detail, liver injury was considered in patients with an increase in ALT or AST of at least 3× ULN, or an increase in ALP, T-Bil or In patients with chronic liver diseases, liver failure was defined according to the acute-on-chronic liver failure (ACLF) consensus recommendations of the Asian Pacific Association for the study of the liver (APASL) [7] .

Acute-on-chronic liver failure is manifested as an acute (within 4 weeks) increase of serum T-Bil ≥85 μmol/L (5 mg/dl) and disorder of coagulation (INR ≥1.5), as well as clinical ascites or encephalopathy (grade ≥2) in a patient with chronic liver disease. 

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Clinical Characteristics of Coronavirus Disease 2019 in China

National Health Commission of China, Guidance for COVID-19: Prevention, Control, Diagnosis and Management

Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection issuspected: interim guidance

Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic

COVID-19 and Liver

COVID-19: Abnormal liver function tests

Clinical Features of COVID-19-Related Liver Functional Abnormality. Clinical gastroenterology and hepatology : the official clinical practice journal of the

Liver tests abnormalities in COVID-19: trick or treat

Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19. Liver international : official journal of the International Association for the Study of the Liver

High Mortality Rates for SARS-CoV-2 Infection in Patients with Pre-existing

Chronic Liver Disease and Cirrhosis: Preliminary Results from an International Registry

Liver diseases in the Asia-Pacific region: a

Inverse association between chronic hepatitis B infection and COVID-19: immune-exhaustion or coincidence? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study

Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries

Guidelines on the management of abnormal liver blood tests

COVID-19: Abnormal liver function tests

European Association for the Study of the Liver. Electronic address eee, Clinical practice guidelines p

Clinical and immunologic features in severe and moderate Coronavirus Disease

American Association for the Study of Liver D, European Association for the Study of the L. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the

Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update

Abnormal admission AST and D-Bil levels at admission were independent predictors of COVID-19 mortality

A novel nomogram was built based on admission AST and D-Bil levels as well as other baseline characteristics to predict the in-hospital mortality of COVID-19

Hepatitis B infection was not found to be associated with the risk of lethal outcome in patients with COVID-19

The authors would like to thank Dr. Ying-jie Tang (Yidu Cloud) for his assistance in data collection and statistical analyses. They would also thank Eisai China Inc. for its contribution to improve the flow and writing of this manuscript, and thank all the frontline medics for their bravery and efforts in treating COVID-19.J o u r n a l P r e -p r o o f